Kvika banki hf.
Offered are bills in the three month series KVB 21 0621, six months series KVB 21 0921 and nine months series KVB 21 1222. Accepted bids in each series are limited to ISK 1,000 million nominal value. Total issuance is limited to ISK 2,000 million.
The auction will be structured as a single-price auctions for each series, meaning that all accepted bids, will be sold to investors at the same price. The lowest accepted price (highest yield) will determine the selling price in each series. The bills are issued in ISK 20 million denominations and will be listed on the Nasdaq Iceland stock exchange. Bids will be accepted until 16:00 hrs on Thursday 18th of March. The Payment and settlement date is 22nd of March 2021.
Further information is available at Kvika banki Capital Markets tel. +354 540 3220 or vixlar@kvika.is
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Scandinavian Investment Group A/S19.9.2025 20:22:33 CEST | Pressemeddelelse
Resultat aktietilbagekøbsprogram 17-19 september 2025
Kensana Health Inc.19.9.2025 19:29:40 CEST | Press release
Kensana Health Lands $120 million from GEM, Fuelling a Global Plant Based Medicine Revolution
Digitalist Group Oyj19.9.2025 19:00:31 CEST | Press release
Digitalist Group structures its financing
Leading Edge Materials Corp.19.9.2025 18:00:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2025
Sironax19.9.2025 17:00:00 CEST | Press release
Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom